FH535, a β-catenin pathway inhibitor, represses pancreatic cancer xenograft growth and angiogenesis

Lu Liu, Qiaoming Zhi, Meng Shen, Fei Ran Gong, Binhua P. Zhou, Lian Lian, Bairong Shen, Kai Chen, Weiming Duan, Meng Yao Wu, Min Tao, Wei Li

Research output: Contribution to journalArticlepeer-review

26 Scopus citations


The WNT/β-catenin pathway plays an important role in pancreatic cancer carcinogenesis. We evaluated the correlation between aberrant β-catenin pathway activation and the prognosis pancreatic cancer, and the potential of applying the β-catenin pathway inhibitor FH535 to pancreatic cancer treatment. Meta-analysis and immunohistochemistry showed that abnormal β-catenin pathway activation was associated with unfavorable outcome. FH535 repressed pancreatic cancer xenograft growth in vivo. Gene Ontology (GO) analysis of microarray data indicated that target genes responding to FH535 participated in stemness maintenance. Realtime PCR and flow cytometry confirmed that FH535 downregulated CD24 and CD44, pancreatic cancer stem cell (CSC) markers, suggesting FH535 impairs pancreatic CSC stemness. GO analysis of β-catenin chromatin immunoprecipitation sequencing data identified angiogenesis-related gene regulation. Immunohistochemistry showed that higher microvessel density correlated with elevated nuclear β-catenin expression and unfavorable outcome. FH535 repressed the secretion of the proangiogenic cytokines vascular endothelial growth factor (VEGF), interleukin (IL)-6, IL-8, and tumor necrosis factor-a, and also inhibited angiogenesis in vitro and in vivo. Protein and mRNA microarrays revealed that FH535 downregulated the proangiogenic genes ANGPT2, VEGFR3, IFN-γ, PLAUR, THPO, TIMP1, and VEGF. FH535 not only represses pancreatic CSC stemness in vitro, but also remodels the tumor microenvironment by repressing angiogenesis, warranting further clinical investigation.

Original languageEnglish
Pages (from-to)47145-47162
Number of pages18
Issue number30
StatePublished - 2016

Bibliographical note

Funding Information:
This work was supported by the National Natural Science Foundation of China (grant numbers 81472296, 81101867, 81272542, 81200369, 81502275, 81572992), the China International Medical Foundation (grant number CIMF-F-H001-057), the Six Major Talent Peak Project of Jiangsu Province (grant number 2015-WSN-022), the Special Foundation of Clinical Medicine of Jiangsu Provincial Bureau of Science and Technology (grant number BL2014039), the Scientific Research Project of Jiangsu Provincial Bureau of Traditional Chinese Medicine (grant number L213236), the Medical Scientific Research Project of Jiangsu Provincial Bureau of Health (grant number Z201206), the Special Foundation of Wu Jieping Medical Foundation for Clinical Scientific Research (grant numbers 320.6753.1225, 320.6750.12242), the Science and Education for Health Foundation of Suzhou for Youth (grant numbers SWKQ1003, SWKQ1011, kjxw2015003), the Science and Technology Project Foundation of Suzhou (grant numbers SYS201112, SYSD2012137, SYS201335, SYS201542, SYS201504), the Science and Technology Foundation of Suzhou Xiangcheng (grant numbers SZXC2012-70, XJ201451, XJ201538) and Transverse Project of Soochow University (grant numbers P112200315, P112200914). We thank the Novel Bioinformatics Company (Shanghai, China) for their technical support in bioinformatics analysis.


  • Angiogenesis
  • Cancer stem cell
  • FH535
  • Pancreatic cancer
  • β-catenin

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'FH535, a β-catenin pathway inhibitor, represses pancreatic cancer xenograft growth and angiogenesis'. Together they form a unique fingerprint.

Cite this